Systemic mastocytosis with associated hematologic neoplasm (SM-AHN) presents unique diagnostic and treatment challenges. In this Medscape-certified activity, experts discuss the complex patient journey, from delayed diagnosis to individualized…
Avapritinib, branded as Ayvakit, became the first FDA-approved treatment for indolent systemic mastocytosis (ISM) in 2023, marking a major advancement for patients. ISM, driven by the KIT D816V…
NEW YORK (Reuters Health) – New research suggests that the routine use of MRI for newly diagnosed breast cancer does not improve margin status or attempts at breast-conserving…
NEW YORK (Reuters Health) – In patients with metastatic renal cell carcinoma, first-line treatment with interferon (IFN)-alpha plus sunitinib or bevacizumab has “clinically relevant and statistically significant” survival…
NEW YORK (Reuters Health) – Adding hormone therapy to radiotherapy for locally advanced prostate cancer reduces disease recurrence and prolongs survival, according to a report in the August…
Robert Shorr, Ph.D, D.I.C, Chief Executive Officer of Cornerstone Pharmaceuticals, talks about his company’s approach to the treatment of cancer by targeting and exploiting specific metabolic pathways with…
NEW YORK (Reuters Health) – The American Society for Radiation Oncology (ASTRO) has released a consensus statement regarding patient selection and best practices in using accelerated partial breast…
NEW YORK (Reuters Health) – New research indicates that anemia, regardless of comorbid disease, is a risk factor for death in very elderly individuals. In the study, incident…
Miguel Materin, MD, Director of Ocular Oncology Section, Yale Eye Center, discusses retinoblastoma and the importance of germline vs somatic mutations in predicting prognosis. Summary: Retinoblastoma can be…
NEW YORK (Reuters Health) – Contrary to common opinion, routine cervical screening can identify early-stage adenocarcinoma and adenosquamous carcinoma of the cervix, according to a large case-control study…
Miguel Materin, MD, Director of Ocular Oncology Section, Yale Eye Center, discusses metastatic eye cancer that can be caused by any cancer, but most commonly carcinomas. Summary: Breast…
Miguel Materin, MD, Director of Ocular Oncology Section, Yale Eye Center, discusses retinoblastoma and treatment options, which include enucleation and radiation, chemotherapy, cryotherapy and TTT (transpulillary thermotherapy protocol).…
